Absci Corp is a pioneering company in the field of generative AI for drug discovery, based in Vancouver, Washington. Founded in 2011, it focuses on uncovering new drug targets and developing biotherapeutic candidates. By leveraging artificial intelligence, Absci aims to accelerate the pace of drug development, making it a key player in the pharmaceutical industry's future.
AMD just filed its first-ever 13F, and buried inside a $1.31 billion portfolio are five positions that trace exactly where the company believes AI infrastructure spending lands next, including one ticker most…
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
